December 2016
-
The American Academy of Allergy, Asthma & Immunology (AAAAI) has published results of three Phase 1 studies of ARS Pharmaceuticals’ ARS-1 (Neffy) intranasal epinephrine that had been scheduled for presentation at the AAAAI annual meeting.… Read more . . .
-
Hovione has announced the appointment of former Evonik executive Jean-Luc Herbeaux as the company’s new Chief Operating Officer. Herbeaux was most recently Senior VP and General Manager of Evonik’s Health Care Business Line. He will… Read more . . .
-
The Finnish Medicines Agency has granted GMP certification to nanonization specialist Nanoform Finland, the company said. In December 2019, Nanoform announced that it had applied for the certification. The company’s CESS (controlled expansion of supercritical… Read more . . .
-
Alnylam Pharmaceuticals and Vir Biotechnology have announced that they intend to meet with the FDA soon regarding an IND for VIR-2703 (ALN-COV), an inhaled siRNA in development for prevention and/or treatment of COVID-19. The companies… Read more . . .
-
3M announced that it has completed the sale of “substantially all” of 3M Drug Delivery Systems to Altaris Capital Partners, and the new company is now known as Kindeva Drug Delivery. The initial announcement of… Read more . . .
-
At its April 2020 meeting, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for Enerzair Breezhaler (QVM149) indacaterol / glycopyrronium / mometasone for the treatment of uncontrolled asthma as… Read more . . .
-
Functional respiratory imaging (FRI) company Fluidda has announced that an FRI study of COVID-19 patients has shown that the virus is resulting in narrowing of small capillaries in the lung, resulting in higher flow pressures… Read more . . .
-
Following the signing of a letter of intent for a sales agreement with Adherium, Monaghan Medical said that it will launch Adherium’s Hailie digital inhaler monitoring platform in the US. The Hailie sensor was approved… Read more . . .
-
According to Lupin, the FDA has tentatively approved the company’s arformoterol tartrate inhalation solution, a generic version of Sunovion’s Brovana, for the treatment of COPD. Sunovion’s final patent covering Brovana expires in November 2021. Brovana… Read more . . .
-
Windtree Therapeutics has announced the enrollment of the first patient in a Phase 2b bridging study of Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS). In March 2020, Windtree announced that Lee Pharmaceuticals… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK